Optimizing the use of thrombolytics in ST-segment elevation myocardial infarction.

Abstract:

:The advent of thrombolytic therapy was a major advance in the treatment of ST-segment elevation myocardial infarction (STEMI). The administration of fibrinolytic reperfusion therapy can reduce mortality rates by as much as 30%, with the greatest benefit observed if therapy is administered soon after symptom onset. Outcomes with thrombolytic therapy are improved if there is adjunctive treatment with aspirin, clopidogrel and an anti-thrombin agent. Although there is evidence that primary percutaneous coronary intervention (PCI) is the most effective reperfusion strategy, the majority of hospitals still do not have PCI capabilities and, thus, thrombolytic therapy remains a cornerstone of treatment for STEMI. Trials of thrombolytic therapy have demonstrated that initial patency rates can approach 85%, but there is still a need for improvement of non-invasive markers that predict failure or re-occlusion of the infarct-related artery. Because of the overwhelming data demonstrating the importance of rapid reperfusion, current studies are examining the role of earlier treatment of patients with STEMI via pre-hospital administration and/or coordinated systems for rapid diagnosis, transfer and delivery of definitive care. Facilitated PCI, a strategy of thrombolytic therapy followed by immediate PCI, has not been shown to be beneficial and current studies are examining the optimal timing of coronary angiography after thrombolytic therapy.

journal_name

Drugs

journal_title

Drugs

authors

Morse MA,Todd JW,Stouffer GA

doi

10.2165/11317670-000000000-00000

subject

Has Abstract

pub_date

2009-10-01 00:00:00

pages

1945-66

issue

14

eissn

0012-6667

issn

1179-1950

pii

5

journal_volume

69

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.

    abstract::During the intervening years since metoprolol was first reviewed in the Journal (1977), it has become widely used in the treatment of mild to moderate hypertension and angina pectoris. Although much data have accumulated, its precise mechanisms of action in these diseases remain largely uncertain. Optimum treatment of...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198631050-00002

    authors: Benfield P,Clissold SP,Brogden RN

    更新日期:1986-05-01 00:00:00

  • Influence of carvedilol on blood glucose and glycohaemoglobin A1 in non-insulin-dependent diabetics.

    abstract::Pharmacological treatment of hypertension can, cause clinically significant alterations in endocrine function and glucose homeostasis. The aim of this study was to investigate the antihypertensive efficacy and the influence on carbohydrate metabolism of carvedilol and metoprolol in non-insulin-dependent diabetics with...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198800366-00023

    authors: Ehmer B,van der Does R,Rudorf J

    更新日期:1988-01-01 00:00:00

  • Postoperative ileus: progress towards effective management.

    abstract::The pathogenesis of postoperative ileus (PI) is multifactorial, and includes activation of inhibitory reflexes, inflammatory mediators and opioids (endogenous and exogenous). Accordingly, various strategies have been employed to prevent PI. As single-modality treatment, continuous postoperative epidural analgesia incl...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262180-00004

    authors: Holte K,Kehlet H

    更新日期:2002-01-01 00:00:00

  • Antiepileptic drug development in children: considerations for a revisited strategy.

    abstract::The European Commission and the European Parliament have acknowledged the specific need for a proper evaluation of new drugs in children. The evaluation of the antiepileptic drugs (AEDs) available on the market illustrates the deficit in therapeutic trials for childhood epilepsy syndromes. Currently, the development o...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868010-00002

    authors: Chiron C,Dulac O,Pons G

    更新日期:2008-01-01 00:00:00

  • Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.

    abstract::Alectinib (Alecensa(®)) is a second-generation, orally active, potent and highly selective inhibitor of anaplastic lymphoma kinase (ALK). Alectinib is approved for the treatment of ALK fusion-gene positive, unresectable, advanced or recurrent non-small cell lung cancer (NSCLC) in Japan, where it has been given orphan ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0329-y

    authors: McKeage K

    更新日期:2015-01-01 00:00:00

  • Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients.

    abstract::The antihypertensive effects of the regular immediate release formulation of verapamil (verapamil IR) and the newer sustained release formulation of verapamil (verapamil SR) were compared in Hispanic patients with untreated essential hypertension. Verapamil IR was given in 3 divided doses (80 or 160mg 3 times daily) a...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-199200441-00002

    authors: Fuenmayor NT,Faggin BM,Cubeddu LX

    更新日期:1992-01-01 00:00:00

  • What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections?

    abstract::The newest (third generation) fluoroquinolones are potentially useful agents in the management of community-acquired respiratory tract infections. This is mainly due to their increased activity against Streptococcuspneumoniae, a pathogen poorly susceptible to the second-generation compounds, and playing a major role i...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199957060-00002

    authors: Momméja-Marin H,Carbon C

    更新日期:1999-06-01 00:00:00

  • Letermovir: First Global Approval.

    abstract::Letermovir (Prevymis™) is an orally or intravenously administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc., under a global license from AiCuris Anti-infective Cures GmbH. Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and diseas...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-017-0860-8

    authors: Kim ES

    更新日期:2018-01-01 00:00:00

  • The challenge of changing healthcare systems.

    abstract::Healthcare systems are in flux throughout the world. Traditional structures and attitudes are changing. The balance of power between political bodies, payers, providers and patients is being destabilised. New approaches by governments and forward integration by drug companies and payers into care management are all ma...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-199600522-00014

    authors: Weber F

    更新日期:1996-01-01 00:00:00

  • The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders.

    abstract::This review focuses on the biochemical and clinical aspects of methylation in neuropsychiatric disorders and the clinical potential of their treatment with ademetionine (S-adenosylmethionine; SAMe). SAMe is required in numerous transmethylation reactions involving nucleic acids, proteins, phospholipids, amines and oth...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199448020-00002

    authors: Bottiglieri T,Hyland K,Reynolds EH

    更新日期:1994-08-01 00:00:00

  • Current treatment recommendations for topical burn therapy.

    abstract::Infections in burn patients continue to be the primary source of morbidity and mortality. Topical antimicrobial therapy remains the single most important component of wound care in hospitalised burn patients. The goal of prophylactic topical antimicrobial therapy is to control microbial colonisation and prevent burn w...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199040030-00004

    authors: Monafo WW,West MA

    更新日期:1990-09-01 00:00:00

  • Emicizumab: A Review in Haemophilia A.

    abstract::Emicizumab (Hemlibra®), a recombinant, humanized, bispecific monoclonal antibody, restores the function of missing activated factor VIII (FVIII) by bridging FIXa and FX to facilitate effective haemostasis in patients with haemophilia A. Subcutaneous emicizumab is approved in several countries, including in the USA and...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01200-2

    authors: Blair HA

    更新日期:2019-10-01 00:00:00

  • [Properties and features of nabumetone].

    abstract::Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) of the 2,6-disubstituted naphthylalkanone class. It is a prodrug metabolised to an active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA), which preferentially inhibits cyclo-oxygenase-2 (COX-2) and has both anti-inflammatory and analgesic properties. The...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:

    authors: Davies NM,McLachlan AJ

    更新日期:2000-01-01 00:00:00

  • Telavancin.

    abstract::Telavancin is the first available lipoglycopeptide antibacterial agent. It is active against Gram-positive bacteria, including meticillin/oxacillin-resistant Staphylococcus aureus (MRSA) strains associated with complicated skin and skin structure infections (cSSSIs). In randomized, double-blind trials, intravenous tel...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/10481380-000000000-00000

    authors: Lyseng-Williamson KA,Blick SK

    更新日期:2009-01-01 00:00:00

  • Nivolumab: a review of its use in patients with malignant melanoma.

    abstract::Nivolumab (Opdivo(®)) is a fully human monoclonal antibody against programmed death receptor-1, a negative regulatory checkpoint molecule with a role in immunosuppression. The drug is administered intravenously and is approved for the treatment of unresectable malignant melanoma in Japan. The potential for intravenous...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0234-4

    authors: Deeks ED

    更新日期:2014-07-01 00:00:00

  • Sitagliptin: a review of its use in the management of type 2 diabetes mellitus.

    abstract::Sitagliptin (Januvia, Glactiv(R), Tesavel(R)) is a dipeptidyl peptidase-4 inhibitor indicated for the treatment of type 2 diabetes mellitus. Oral sitagliptin as monotherapy or combination therapy was generally well tolerated and improved glycaemic control in well designed clinical trials in patients with type 2 diabet...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11203790-000000000-00000

    authors: Dhillon S

    更新日期:2010-03-05 00:00:00

  • The prevalence of hypertension in the United States today.

    abstract::The simplest response to the question, what is the prevalence of hypertension in the United States today?, is given by a currently popular slogan: 23,000,000 Americans have hypertension. It is clear that the problem is large in scale, but this figure alone is an insufficient guide to many practical issues. The prevale...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-197600111-00006

    authors: Labarthe DR

    更新日期:1976-01-01 00:00:00

  • Cost effectiveness of quinolones in hospitals and the community.

    abstract::In hospitals, oral quinolone therapy has lower daily associated costs (acquisition and administration) than most intravenous regimens. In addition, oral switch therapy shortens the duration of hospital stay for most patients. However, randomised trials are required to measure the economic impact of the switch to oral ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958002-00014

    authors: Davey P

    更新日期:1999-01-01 00:00:00

  • Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity.

    abstract::Sodium-glucose co-transporter 2 (SGLT2) inhibitors are glucose-lowering drugs that reduce plasma glucose levels by inhibiting glucose and sodium reabsorption in the kidneys, thus resulting in glucosuria. Their effects consequently include reductions in HbA1c, blood glucose levels, and blood pressure, but also reductio...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-1057-0

    authors: Pereira MJ,Eriksson JW

    更新日期:2019-02-01 00:00:00

  • Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.

    abstract::Osteoporosis is a systemic bone disease characterized by low bone mass and bone mineral density, and deterioration of the underlying structure of bone tissue. These changes lead to an increase in bone fragility and an increased risk for fracture, which are the clinical consequences of osteoporosis. The classical triad...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11587570-000000000-00000

    authors: Reginster JY

    更新日期:2011-01-01 00:00:00

  • Bronchopulmonary infection due to B. catarrhalis. Clinical features and therapeutic response.

    abstract::A study was made of the clinical features and therapeutic response of 144 patients from whose sputum Branhamella catarrhalis was isolated. Typically, features of bronchopulmonary infection with cough productive of moderate amounts of purulent sputum, fever and dyspnoea were present. Of 74 patients who were infected in...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198600313-00023

    authors: McLeod DT,Ahmad F,Croughan MJ,Calder MA

    更新日期:1986-01-01 00:00:00

  • Mometasone/formoterol inhalation aerosol: in asthma uncontrolled on medium- or high-dose inhaled corticosteroids.

    abstract::The corticosteroid mometasone and the long-acting β(2)-selective adrenoreceptor agonist formoterol have been combined in a single pressurized metered-dose inhaler for use in patients aged ≥12 years with asthma. In a 26-week well designed trial in patients with persistent asthma uncontrolled on medium-dose inhaled cort...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11206920-000000000-00000

    authors: Frampton JE

    更新日期:2012-06-18 00:00:00

  • Pharmacotherapeutic management of locally advanced prostate cancer: current status.

    abstract::Locally advanced prostate cancer (LAPC) is a heterogeneous entity usually embracing T3-4 and/or pelvic lymph-node-positive disease in the absence of established metastases. Outcomes for LAPC with single therapies have traditionally been poor, leading to the investigation of adjuvant therapies. Prostate cancer is a hor...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11591500-000000000-00000

    authors: Martin JM,Supiot S,Berthold DR

    更新日期:2011-05-28 00:00:00

  • The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

    abstract::The endothelin family of peptides are extremely potent endogenous vasoconstrictor and pressor agents. Of the 3 isoforms, endothelin-1 is the major isoform produced by the vascular endothelium and is, therefore, likely to be of most importance for regulation of vascular function. Two endothelin receptor subtypes have s...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199651010-00003

    authors: Ferro CJ,Webb DJ

    更新日期:1996-01-01 00:00:00

  • Safety and tolerance data from the Belgian multicentre study of anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction.

    abstract::In the European Multicentre Study (EMS), the safety and efficacy of a single 30U intravenous injection of anisoylated plasminogen streptokinase activator complex (APSAC) was studied in patients with acute myocardial infarction. The present study discusses the Belgian data on safety and tolerance from the EMS study. 87...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198700333-00055

    authors: Bossaert LL

    更新日期:1987-01-01 00:00:00

  • Cefixime. A review of its therapeutic efficacy in lower respiratory tract infections.

    abstract::Cefixime is an orally active third generation cephalosporin with in vitro antibacterial activity against most important lower respiratory pathogens. The drug is active against Haemophilus influenzae, Moraxella catarrhalis and penicillin-susceptible Streptococcus pneumoniae but not Staphylococcus aureus. Cefixime has a...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199549060-00010

    authors: Markham A,Brogden RN

    更新日期:1995-06-01 00:00:00

  • HDL-cholesterol as a risk factor in coronary heart disease. An update of the Helsinki Heart Study.

    abstract::The aim of the Helsinki Heart Study, a 5-year primary prevention placebo-controlled study involving 4081 dyslipidaemic men (aged 40 to 55 years), was to investigate if increasing high density lipoprotein (HDL)-cholesterol plasma levels and decreasing low density lipoprotein (LDL)-cholesterol levels would reduce the in...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-199000401-00004

    authors: Frick MH,Manninen V,Huttunen JK,Heinonen OP,Tenkanen L,Mänttäri M

    更新日期:1990-01-01 00:00:00

  • Inotuzumab Ozogamicin: First Global Approval.

    abstract::Intravenous inotuzumab ozogamicin (Besponsa®; Pfizer) is an anti-CD22 monoclonal antibody-calicheamicin conjugate that binds to CD22-expressing tumour cells. Upon binding, the complex is internalised and the cytotoxic calicheamicin derivative is released inside the cell, inducing double-strand DNA breakage and subsequ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-017-0802-5

    authors: Lamb YN

    更新日期:2017-09-01 00:00:00

  • Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia.

    abstract::Filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF), has identical biological activity to that of endogenous human G-CSF, but differs in that it contains an N-terminal methionine residue and is not glycosylated. It principally stimulates activation, proliferation and differentiation of neutro...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199448050-00007

    authors: Frampton JE,Lee CR,Faulds D

    更新日期:1994-11-01 00:00:00

  • Glipizide: a review of its pharmacological properties and therapeutic use.

    abstract::Glipizide is a 'second generation' oral hypoglycaemic agent similar in potency to glibenclamide. It is completely absorbed after oral administration and has a rapid onset of action, but the duration of its hypoglycaemic effect is shorter than that of glibenclamide. It is rapidly metabolised to inactive metabolites whi...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197918050-00001

    authors: Brogden RN,Heel RC,Pakes GE,Speight TM,Avery GS

    更新日期:1979-11-01 00:00:00